Polyarteritis nodosa is an uncommon disease characterized by the necrotizing inflammation of medium-sized arteries. Our company specializes in developing diagnostics for rare diseases such as polyarteritis nodosa and offers IVD products, point-of-care testing, and companion diagnostic development services.

Overview of Polyarteritis Nodosa

Polyarteritis nodosa is a rare disorder with an estimated prevalence of around 31 cases per million individuals. Its presentation is diverse, with many individuals experiencing common symptoms like weakness, fever, and unintended weight loss. Although polyarteritis nodosa can affect various organs, it primarily impacts the skin, nervous system, and gastrointestinal tract.

The development of polyarteritis nodosa involves immune system dysregulation, which activates immune cells and releases pro-inflammatory cytokines. This immune response targets arterial walls, leading to vasculitis and subsequent tissue damage.

Fig.1 Histology of muscle biopsy in polyarteritis nodosa. (Hočevar, A., et al., 2021)

Biomarkers Development for Polyarteritis Nodosa

Biomarkers play a crucial role in the diagnosis, monitoring, and management of various diseases, it is also the foundation for developing IVD products. Here is an overview of the progress in biomarker development for polyarteritis nodosa.

Autoantibodies

In individuals with polyarteritis nodosa who exhibit skin-related symptoms, anti-phosphatidylserine-prothrombin complex (anti-PSPT) antibodies could be a biomarker. Research continues to explore the presence of specific autoantibodies that aid in early diagnosis of polyarteritis nodosa.

Genetic Markers

Genetic indicators could assist in recognizing those predisposed to polyarteritis nodosa and shed light on the genetic elements. Evidence suggests that loss-of-function mutations in the gene responsible for adenosine deaminase 2 (ADA2) could result in polyarteritis nodosa vasculopathy.

Cytokines

Studies have concentrated on pinpointing specific cytokines and chemokines that influence the development of polyarteritis nodosa. Higher levels of interferon-γ (IFN-γ) and interleukin 2 (IL-2) in the bloodstream, along with increased IL-8 levels, have shown connections to polyarteritis nodosa.

IVD Kits for Polyarteritis Nodosa

Our Services

Centered on enhancing diagnostic precision, unraveling disease mechanisms, and developing more effective therapeutic strategies to improve individual outcomes, our company delivers comprehensive diagnostic development services. These encompass IVD products, point-of-care testing, and companion diagnostic development services for polyarteritis nodosa.

Equipped with a team of specialists and state-of-the-art technology, our company delves deeply into disease mechanisms, diagnostic hurdles, and potential polyarteritis nodosa-specific biomarkers. If our services intrigue you, please don't hesitate to reach out for further insights and pricing details on relevant services.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.